- Current report filing (8-K)
July 29 2009 - 5:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2009
ONYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
0-28298
|
|
94-3154463
|
(State of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
2100 Powell Street
Emeryville, California 94608
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(510) 597-6500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM 8.01 OTHER EVENTS
On July 29, 2009, Bayer HealthCare Pharmaceuticals Corporation, or Bayer, in its Q2 2009 Analyst
and Investor Briefing, announced net sales of Nexavar for the quarter ending June 30, 2009 of
147 million. Quarterly Nexavar sales are translated into U.S. dollars based on an average
exchange rate over the period. The approximate average exchange rate for the quarter ending June
30, 2009 was $1.36 for
1. Under the Collaboration Agreement between Bayer and Onyx, Bayer and
Onyx share profits from global Nexavar sales, except in Japan where Onyx receives a single digit
royalty on Nexavar net sales.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
ONYX PHARMACEUTICALS, INC.
|
|
Dated: July 29, 2009
|
By:
|
/s/ Matthew K. Fust
|
|
|
|
Matthew K. Fust
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles